These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 26116557)

  • 1. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
    Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
    Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
    J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
    Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
    Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
    Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
    Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
    Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
    Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
    Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
    Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease.
    Theodoraki E; Orfanoudaki E; Foteinogiannopoulou K; Andreou NP; Gazouli M; Koutroubakis IE
    Int J Colorectal Dis; 2022 Mar; 37(3):639-646. PubMed ID: 35013823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
    Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
    Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Anti-Tumour Necrosis Factor Trough Concentrations--Only a Cost Issue or Also Hidden Dangers Ahead?
    Vande Casteele N; Vermeire S
    J Crohns Colitis; 2015 Nov; 9(11):943-4. PubMed ID: 26351380
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME; Werida RH; Radwan MA; Askar SR; Omran GA; El-Mohamdy MA; Hagag RS
    Inflammopharmacology; 2024 Oct; 32(5):3259-3269. PubMed ID: 38985232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.
    Bodini G; Demarzo MG; Saracco M; Coppo C; De Maria C; Baldissarro I; Savarino E; Savarino V; Giannini EG
    Scand J Gastroenterol; 2019 Oct; 54(10):1220-1225. PubMed ID: 31553630
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY; Lee Y; Choe BH; Kang B
    Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.